Kathleen D'Aguanno, Sofianne Gabrielli, Lydia Ouchene, Anastasiya Muntyanu, Moshe Ben-Shoshan, Xun Zhang, Lisa Iannattone, Elena Netchiporouk
Bullous pemphigoid (BP) is an autoimmune blistering skin disease. Current treatment strategies are limited by their efficacy and/or side effect profile and the need for safer and effective alternatives is undeniable. We aimed to conduct a systematic review focusing on the efficacy and safety of omalizumab in BP patients. Embase, PubMed, Cochrane, and clinicaltrials.gov were searched for English and French articles published from inception to July 1, 2021, using search terms "omalizumab" OR "Xolair" OR "IGE025" OR "olizumab" AND "bullous pemphigoid...
July 2022: Journal of Cutaneous Medicine and Surgery